14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Mar 31, 2026
ITRM vs CLSD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Mar 31, 2026, Iterum Therapeutics plc Ordinary Share (ITRM) captures the overall head-to-head institutional edge over Clearside Biomedical, Inc. (CLSD) on higher Unified Composite conviction (50.5/100 HOLD vs. 43.3/100 HOLD) after splitting the core matrix 3–2 (led by Profitability & Quality), while CLSD wins 2–1 across the 6-pillar growth and valuation breakdown. ITRM trades at $0.03 (N/M Forward P/E, -1982.3% operating margin) versus CLSD at $0.41 (N/M Forward P/E, -3502.5% operating margin).
Growth vs. Quality Trade-Off: ITRM earns the overall head-to-head edge with a stronger Unified Composite Score (50.5/100 HOLD vs. CLSD 43.3/100 HOLD) and 1.61β · 508% Vol risk profile, whereas CLSD leads top-line expansion (-80.6% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: ITRM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9); meanwhile CLSD trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 17.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ITRM vs CLSD. Trailing 12-month operating profitability (ITRM -1982.3% vs CLSD -3502.5%) and valuation multiples (ITRM N/M vs CLSD N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Pharmaceutical Preparations value chain with $2.9M market capitalization and -3502.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ITRM vs CLSD Key Questions & Quantitative Answers
As of Mar 31, 2026, Iterum Therapeutics plc Ordinary Share (ITRM) captures the overall head-to-head institutional edge over Clearside Biomedical, Inc. (CLSD) on higher Unified Composite conviction (50.5/100 HOLD vs. 43.3/100 HOLD) after splitting the core matrix 3–2 (led by Profitability & Quality), while CLSD wins 2–1 across the 6-pillar growth and valuation breakdown. ITRM trades at $0.03 (N/M Forward P/E, -1982.3% operating margin) versus CLSD at $0.41 (N/M Forward P/E, -3502.5% operating margin). Growth vs. Quality Trade-Off: ITRM earns the overall head-to-head edge with a stronger Unified Composite Score (50.5/100 HOLD vs. CLSD 43.3/100 HOLD) and 1.61β · 508% Vol risk profile, whereas CLSD leads top-line expansion (-80.6% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ITRM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9); meanwhile CLSD trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 17.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CLSD leads the Growth & Scale pillar: ITRM posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on $390,000 TTM revenue (29.7% gross margin, -1982.3% operating margin), compared with CLSD at -80.6% YoY revenue growth and +0.0% YoY earnings growth on $3.3M TTM revenue (88.1% gross margin, -3502.5% operating margin). On trailing 12-month operating scale, ITRM generates $390,000 in USD-normalized revenue versus $3.3M for CLSD. In operating R&D and SG&A reinvestment, ITRM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CLSD.
CLSD screens cheaper on headline valuation multiples. ITRM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin), whereas CLSD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ITRM (-555.7% ROE) versus CLSD (-1310.0% ROE) capital efficiency.
In options market volatility and institutional positioning, ITRM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.61β · 508% Vol realized risk). By comparison, CLSD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.24β · 269% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Mar 31, 2026. For educational research only; not investment advice.